With a $50,000 grant from FRAXA Research Foundation from 2002-2003, Dr. Carl Dobkin and his team at the New York Institute for Basic Research studied the causes for heightened seizure activity in Fragile X mice. Results published.
Read moreResearcher
Isolating and Characterizing the mRNAs That Bind FMRP
With $60,000 in grants from FRAXA Research Foundation from 1998-1999, Dr. Robert Denman and his team at the New York State Institute for Basic Research explored how FMRP possibly functions.
Read moreTreatment of a Mouse Model of Fragile X Syndrome with MPEP
With a $49,000 grant from FRAXA Research Foundation in 2003, Dr. Linda Crnic at the University of Colorado continued studies of MPEP in Fragile X mice, exploring whether chronic use improves symptoms of Fragile X syndrome without impairing cognitive function.
Read moreStructure of FMRP
With a $68,000 grant from FRAXA Research Foundation from 2001-2002, Dr. Lynne Regan at Yale University studied different protein shapes and how they contributed towards different functions for Fragile X syndrome. Results published.
Read moreProspects For Gene Therapy in the Fragile X
With a $90,000 grant from FRAXA Research Foundation from 2000-2002, Dr. Mario Rattazzi at the New York State Institute for Basic Research explored gene therapy: ways to transfer the FMR1 gene across the blood-brain-barrier in normal rats and mice, and then in FMR1 knockout mice. Results published.
Read moreA Genetic Screen For Dominant Modifiers of Drosophila (Fruitfly) FMR
With a $35,000 grant from FRAXA Research Foundation in 2002, Dr. Kevin Moses and his team at Emory University studied fruit fly eye phenotypes to screen for genes that function in the Fragile X pathway.
Read moreStudies of glutamate receptor trafficking
FRAXA awarded $35,000 in 2001 to Robert Malinow, PhD, Principal Investigator and Julius Zhu, PhD, FRAXA Postdoctoral Fellow at Cold Spring Harbor Laboratory. While he was a postdoctoral fellow in Dr. Malinow’s lab, Dr. Julius Zhu carried out experiments designed to define the set of proteins which are affected in Fragile X syndrome and understand how they function together. In 2002, Dr. Zhu started his own lab at the University of Virginia where he is continuing his Fragile X work with new funding from FRAXA.
Read morePrepulse Inhibition in Fragile X
With a $27,000 grant from FRAXA Research Foundation in 1999, Dr. Alcino Silva and his team examined prepulse inhibition in Fragile X mice and children with Fragile X.
Read moreIdentification of Specific RNA Targets of FMRP
With a $70,000 grant from FRAXA Research Foundation from 1999-2001, Dr. Robert Darnell and his team at Rockefeller University made significant contributions towards understanding how FMRP functions and how the brain is affected without it. Results published.
Read moreTransgenic Mouse Model Studies of Fragile X Syndrome
With a $410,000 grant from FRAXA Research Foundation from 1999-2001, Dr. Eric Kandel and his team at Columbia University researched development of Fragile X mice to further aid future studies of Fragile X research.
Read moreStartle Modulation in Males with Fragile X Syndrome
With a $42,720 grant from FRAXA Research Foundation in 2001, Dr. Elisabeth Dykens at Vanderbilt University showed that startle and prepulse inhibition (PPI) are very much affected in young males are particularly affected by Fragile X syndrome. Results published.
Read moreMolecular Interactions Between FMRP and Protein Translation Apparatus
With a $65,000 grant from FRAXA Research Foundation from 2000-2001, Dr. Claudia Bagni focused on understanding the specific molecular interactions which regulate protein synthesis, and how they are altered in Fragile X. Dr. Bagni has moved from the University of Rome to VIB in Leuven, Belgium. Results published.
Read moreTranscriptional Regulation of the Fragile X Gene (fmr1) in the Olfactory Bulb
With a $35,000 in grant from FRAXA Research Foundation, Dr. Justin Fallon and his team at Brown University studied systematic mapping of Fragile X granules in developing mouse brains, revealing a potential role for presynaptic FMRP in sensorimotor functions.
Read moreRole of FMRP in Development and Maturation of Spine Synapses
With a $160,000 grant from FRAXA Research Foundation from 1999-2000, Drs. Menahem Segal at the Weizmann Institute and Katarina Braun at the Leibnitz Institute for Learning researched the development of Fragile X syndrome in a controlled, in vitro test system. Results published.
Read moreNeural Network Model of Working Memory in Fragile X Syndrome
With a $67,000 grant from FRAXA Research Foundation in 2000, Dr. Mina Johnson-Glenberg at the University of Wisconsin researched how long-term and working memory was affected in individuals with Fragile X syndrome.
Read moreMelatonin Clinical Trial in Fragile X
With a $60,000 grant from FRAXA Research Foundation from 1998-1999, Dr. Randi Hagerman and her team at the University of California studied the effects of different compounds on individuals with Fragile X syndrome, focusing specifically on melatonin. Results published.
Read moreFMR1 Gene Regulation
With a $30,000 grant from FRAXA Research Foundation in 1999, Dr. Paul Hagerman and his team at the University of California researched how to re-activate the FMR1 gene and how to measure its levels.
Read moreLongitudinal Study of Children with Fragile X
With a $30,000 grant from FRAXA Research Foundation in 2000, Dr. Don Bailey and his team at the University of North Carolina studied the longitudinal development of children, with a focus on educational strategies and development of language. They have contributed greatly to our understanding of the course of Fragile X over a lifetime, as well as the frequency of autism and other behavioral complications in the Fragile X population.
Read moreTransport of the Fragile X Protein
With a $123,000 grant from FRAXA Research Foundation from 1998-2000, Dr. Alan Tartakoff at the Case Western Reserve University studied how proteins communicate with the brain, how and when FMRP travels in the brain, and how to introduce more antibodies to Fragile X research.
Read moreCharacterization of Two Novel FMRP Interacting Proteins
With a $30,000 grant from FRAXA Research Foundation in 2000, Dr. Jean-Louis Mandel and his team at the University of Strasbourg studied the function of two proteins to better understand the affects of the absence of FMRP.
Read moreSynaptic Plasticity and Olfactory Learning in Fragile X
With a $40,000 grant from FRAXA Research Foundation in 2000, Dr. John Larson and his team at the University of Illinois Chicago used olfaction (sense of smell) in mice as a neuro-behavioral model system for human memory. They characterized olfactory sensitivity, learning, and memory in FMR1 knockout mice as compared to wild-type (normal control) mice.
Read moreReactivation of the FMR1 Gene in Fragile X Patients Cells in Culture
With a $62,000 grant from FRAXA Research Foundation from 1999-2000, Dr. Giovanni Neri and his team at Universita Cattolica del S. Cuore explored possible strategies to turn the Fragile X gene back on.
Read moreImaging of Neocortical Dendritic Spine Maturation in FMR1 Knockout Mice Using Two-Photon Laser Scanning Microscopy
With $30,000 in funding from FRAXA Research Foundation in 1999, Dr. Karel Svoboda and his team at the Cold Spring Harbor Laboratory explored the changing nature of dendritic spine motility by imaging neocortical circuits in Fragile X mice.
Read morePsychophysiological Measures of Arousal: Documentation of Treatment Effects & Impact of Disability
With a $60,000 grant from FRAXA Research Foundation from 1998-2000, Dr. Don Bailey and his team at the University of North Carolina explored the role of arousal in individuals that are affected by Fragile X syndrome.
Read moreImproving Memory Reversal Testing and Treatment with AMPAkines in the Fragile X Knock-Out Mouse
A two year $62,000 FRAXA grant was been awarded to W. Ted Brown, MD, PhD from 1997-1998. The Principal Investigator at the Institute For Basic Research in New York aims to develop an improved test to show learning deficits in the FMR1 knock-out mouse model of Fragile X, and test experimental drugs (Ampakines) that may be effective in treating these deficits.
Read more